Abdera is developing targeted alpha therapies (TATs) using its ROVEr™ platform, which combines antibody engineering with radiopharmaceuticals to deliver radionuclide payloads directly to solid tumors. The company aims to improve treatment outcomes for patients with relapsed, refractory, and metastatic cancers while minimizing systemic toxicities.

Akero Therapeutics is developing Efruxifermin (EFX), a therapeutic agent aimed at treating metabolic dysfunction-associated steatohepatitis (MASH) by restoring metabolic balance in patients. The company conducts clinical trials to evaluate the efficacy of EFX in reversing the progression of this serious liver disease.

Aligos Therapeutics is developing targeted small molecule therapies for liver and viral diseases, utilizing medicinal chemistry to create best-in-class oral agents like ALG-055009 for metabolic dysfunction-associated steatohepatitis and ALG-000184 for chronic hepatitis B. The company addresses the significant unmet medical needs for more effective treatments in these areas, aiming to improve patient outcomes.

Allrock Bio develops oral, highly selective ROCK1/2 small‑molecule inhibitors to treat rare cardiopulmonary diseases such as pulmonary arterial hypertension and associated fibrotic lung conditions. By integrating pre‑clinical data, Phase 1 PK/PD modeling, and biomarker‑driven trial designs, the company accelerates the clinical development of disease‑modifying therapies for pharmaceutical partners and healthcare providers.

Altergo is a digital twin and data analytics platform that provides real-time monitoring and performance insights for energy storage systems (ESS) and battery management. The platform enhances operational efficiency by enabling predictive maintenance and optimizing asset utilization, reducing downtime and operational costs.

Andira Pharmaceuticals develops cannabinoid‑based therapeutics and medical devices that use synergistic cannabinoid combinations to improve outcomes for post‑surgical pain, chronic wounds, and early‑stage breast cancer. Their pipeline includes a transdermal analgesic (AND‑254), a localized breast‑cancer therapy (AND‑259), and the Silvanex™ platform, a triple‑synergy silver‑cannabinoid formulation that provides broad antimicrobial activity and promotes tissue repair.

Antag Therapeutics is developing first‑in‑class GIP receptor antagonist peptides, such as AT‑7687, to treat obesity, type 2 diabetes, and related metabolic disorders. By blocking the GIP pathway that drives fat storage and insulin resistance, their approach aims to achieve meaningful weight loss and metabolic improvement while preserving lean mass and maintaining tolerability. The lead candidate is in Phase 1a trials as both a monotherapy and in combination with other obesity therapies.

Belharra’s Searchlight™ platform uses a photoaffinity‑based chemoproteomic library to map functional, non‑covalent binding pockets across the entire proteome in live cells. By combining high‑throughput mass spectrometry, bioinformatic analysis, and cellular screening, it delivers unbiased, proteome‑wide pocket discovery that supports pharmaceutical and biotech R&D in expanding target space for drug development.

Black Diamond Therapeutics develops MasterKey therapies that target genetically defined cancers, specifically non-small cell lung cancer and glioblastoma, by addressing multiple oncogenic mutations with a single treatment approach. This technology aims to overcome resistance mechanisms and reduce toxicities associated with wild-type proteins, enhancing treatment efficacy for a broader patient population.

Borealis Biosciences develops RNA therapeutics specifically targeting kidney diseases, utilizing advanced methods for targeted delivery to renal cells. The company addresses the lack of effective treatments for prevalent chronic kidney conditions, aiming to improve patient outcomes and reduce the incidence of kidney failure.

Bright Peak utilizes a proprietary chemical protein synthesis platform to develop multifunctional precision immunotherapies targeting cancer and autoimmune diseases. Their approach aims to enhance treatment efficacy by creating novel designer immunotherapies that address the limitations of existing therapies.

Capsida Biotherapeutics develops targeted, intravenously administered gene therapies using proprietary engineered capsids that achieve over 70% neuronal expression while minimizing liver targeting. The company focuses on treating rare and common central nervous system disorders, including STXBP1 developmental and epileptic encephalopathy and Parkinson’s disease associated with GBA mutations.

Century Therapeutics develops allogeneic, induced pluripotent stem cell (iPSC)-derived NK and T cell therapies to treat hematological and solid tumor malignancies, as well as autoimmune diseases. Their platform addresses the limitations of existing cell therapies by providing scalable, fit-for-purpose products with enhanced functionalities.

Chance Pharmaceuticals is a clinical-stage biotechnology company developing inhalation therapies for respiratory and central nervous system diseases using a proprietary virtual reality drug development platform. The company focuses on improving drug formulations and expanding the application of biologics in inhalation treatments to enhance patient quality of life.

Chinook Therapeutics develops targeted therapeutics that focus on addressing significant disease burdens, particularly in kidney diseases. By utilizing advanced biological research and technology, the company aims to enhance patient outcomes and extend life expectancy.

Cimeio Therapeutics develops gene-editing technologies that create shielded hematopoietic stem cells (HSCs) to protect healthy cells during immunotherapy for leukemic tumors and autoimmune diseases. This approach enhances the safety and efficacy of hematopoietic stem cell transplants and adoptive cell therapies by preventing depletion of healthy cells while targeting diseased ones.

CRISPR Therapeutics develops curative gene‑editing medicines using CRISPR/Cas9 technology, creating both ex vivo cell therapies and in vivo lipid‑nanoparticle delivery approaches. Its pipeline targets serious genetic, hematologic, metabolic, oncologic and rare diseases, aiming to provide one‑time, disease‑modifying treatments for patients.

Den is a multisig wallet solution that enables onchain teams to execute secure transactions quickly, allowing users to send both crypto and fiat, swap tokens, and interact with decentralized applications. By automating signer coordination and transaction simulations, Den eliminates the inefficiencies of manual approvals and enhances transaction safety, having facilitated over $1 billion in transactions for more than 400 teams.

Firefly Bio develops Degrader Antibody Conjugates (DACs) by integrating selective protein degraders with the capabilities of traditional ADCs. Their proprietary platform enables the highly specific delivery of these novel degraders directly to target tissues. This technology allows for the scalable access and utilization of new classes of ADC payloads.

Gate Bioscience is developing Molecular Gates, small molecule drugs that selectively block disease-causing extracellular proteins from being secreted by targeting the secretory translocon within cells. By preventing the emergence of these harmful proteins, the company aims to eliminate diseases linked to over 1,000 identified extracellular proteins.

Gotham Therapeutics is developing a novel drug class that targets the epitranscriptomics machinery to modulate gene expression and cellular processes. This approach aims to address diseases linked to dysregulated RNA modifications, providing a new therapeutic avenue for conditions currently lacking effective treatments.

Helicore Bio uses a proprietary antibody‑peptide conjugate platform to create long‑acting obesity and cardiometabolic therapies that can be administered quarterly or less frequently. By linking stable, biased GLP‑1 agonist or selective amylin agonist peptides to a GIP ligand‑binding antibody, the company delivers potent metabolic drugs with extended systemic exposure and demonstrated Phase 1 safety.

Hopae provides Digital Identity as a Service, utilizing advanced identity and access management technologies to ensure secure and privacy-preserving digital interactions. The platform prevents forgery and maintains data sovereignty, enabling users to verify their identities while safeguarding personal information in compliance with regulations.

Kion provides a cloud enablement solution that simplifies cloud management and governance through automated policy enforcement and resource optimization. This technology helps organizations reduce operational complexity and enhance compliance across their cloud environments.